Journal
EPILEPSIA
Volume 49, Issue -, Pages 56-62Publisher
WILEY
DOI: 10.1111/j.1528-1167.2008.01927.x
Keywords
Antiepileptic drugs; Generic substitution; Pharmacokinetics; Bioequivalence
Categories
Funding
- GSK
- Sanofi-Aventis
- Novartis
- Janssen-Cilag
- Pfizer
- UCB
- Eisai
- Abbott Labs
Ask authors/readers for more resources
The role of generic drugs in both the US and global marketplace has been steadily increasing over the last few years. Although generic drugs clearly represent an important economic alternative for many patients, there are reasons for concern in certain disease states. Recently, the substitution of antiepileptic drugs in patients with epilepsy has gained increased attention. Concerns over potential therapeutic inequivalence has prompted many clinicians to question current regulatory requirements for both establishing bioequivalence, as well as product substitution. The objective of this article is to present arguments both for and against the use of generic drugs and practice of generic substitution in patients with epilepsy. Regulatory requirements, pharmacokinetic methodology, and biopharmaceutical considerations are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available